Amgen Inc. (AMGN) received recent rating updates from Argus Research and Guggenheim following its strong fiscal Q4 and full-year 2025 results, which showed double-digit growth in revenues and EPS. Argus reiterated a Buy rating with a $400 price target, while Guggenheim reaffirmed a Hold rating with a $347 price target. The biotechnology company reported record sales for many products and expects total revenues between $37.0 billion and $38.4 billion for 2026.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Here's What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
Amgen Inc. (AMGN) received recent rating updates from Argus Research and Guggenheim following its strong fiscal Q4 and full-year 2025 results, which showed double-digit growth in revenues and EPS. Argus reiterated a Buy rating with a $400 price target, while Guggenheim reaffirmed a Hold rating with a $347 price target. The biotechnology company reported record sales for many products and expects total revenues between $37.0 billion and $38.4 billion for 2026.